AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$JNJ

Schmid Timothy sold $9.2M of JNJ

Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares of JOHNSON & JOHNSON (JNJ) at $274.74 ($9.23M total) across 2 trades on 2026-09-02.

Original reporting
SEC EDGAR · Schmid Timothy
Published Sep 4, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$JNJ
Bearish
medium confidence
Mentioned
$JNJ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJBearishLow
01

Why it matters

The disclosed sale represents a material reduction in the insider's stake, which may influence short-term trading sentiment.

02

Market read

The filing is a primary source event with material size, relevant for traders monitoring insider activity in large-cap pharma.

03

What to watch

No accompanying earnings or guidance change; sale may be unrelated to company fundamentals.

Relevance 6/10Novelty 8/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering timely insight into insider sentiment.

Company-level read

Ticker impact

$JNJBearishMedium confidence
Context

SEC Form 4 disclosed Timothy Schmid sold 33,597 shares of Johnson & Johnson for $9.23M on 2026-09-02.

Expected impact

Possible modest dip in JNJ price over the next few days.

Evidence & confidence

Executive-level insider sale exceeding $5M is material; market may interpret as a negative signal, but no other catalyst is present.

Market effects

Sector

Minimal impact on healthcare sector; isolated to JNJ.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking large-cap pharma stocks.

Counterpoint

What could challenge this read

Insider sell could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Officer
    Timothy Schmid

    Executive Vice President, Worldwide Chair, MedTech at Johnson & Johnson.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JNJ insider trading history →

Related articles

OCT 15
$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

investing.com2 min
OCT 14
$JNJMedAI 8/10

Johnson & Johnson CFO taps internal investment for medtech growth

Johnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.

finance.yahoo.com2 min
OCT 14
$JNJHigh

Johnson & Johnson PR: Tylenol Recall to Talc Settlement

Johnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.

everything-pr.com2 min
OCT 14
$JNJHighAI 8/10

J&J posts weak medical device sales, shares fall

Johnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.

manilatimes.net2 min